GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Beta

BLIS Technologies (NZSE:BLT) Beta : 1.04 (As of Jun. 07, 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-07), BLIS Technologies's Beta is 1.04.


BLIS Technologies Beta Historical Data

The historical data trend for BLIS Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Beta Chart

BLIS Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.79 0.98 1.37 0.98

BLIS Technologies Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.98 1.37 0.87 0.98

Competitive Comparison of BLIS Technologies's Beta

For the Biotechnology subindustry, BLIS Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Beta distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Beta falls into.



BLIS Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


BLIS Technologies  (NZSE:BLT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BLIS Technologies Beta Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015